Abstract
Plasmid DNA (pDNA) expression vectors are fundamental to all forms of non-viral gene transfer. In this review, we discuss principles of pDNA design and production including the impact of bacterially derived sequences on transgene expression and minicircle approaches to minimize their effects. The impact of inclusion of DNA elements such as scaffold matrix attachment regions (S/MARs), transcription factor (TF)-binding sites and tissue-specific promoters are described. The benefits of eliminating CG dinucleotides (CpGs) from the pDNA are also considered.
Similar content being viewed by others
References
Gao X, Kim KS, Liu D . Nonviral gene delivery: what we know and what is next. AAPS J 2007; 9: E92–E104.
Lufino MM, Edser PA, Wade-Martins R . Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008; 16: 1525–1538.
Wang Z, Jin L, Yuan Z, Wegrzyn G, Wegrzyn A . Classification of plasmid vectors using replication origin, selection marker and promoter as criteria. Plasmid 2009; 61: 47–51.
Gene transfer medicinal products for human use. European Pharmacopoeia 2007; 6.0: 667–676.
Azzoni AR, Ribeiro SC, Monteiro GA, Prazeres DM . The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression. J Gene Med 2007; 9: 392–402.
Wooddell CI, Reppen T, Wolff JA, Herweijer H . Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery. J Gene Med 2008; 10: 551–563.
Ribeiro SC, Monteiro GA, Prazeres DM . Evaluation of the effect of non-B DNA structures on plasmid integrity via accelerated stability studies. J Pharm Sci 2008; doi:10.1002/jps.21503.
FDA. Guidance for industry: considerations for plasmid deoxyribonucleic acid vaccines for infectious disease indications. Fed Regist 2007; 72: 61172.
Zhang X, Epperly MW, Kay MA, Chen ZY, Dixon T, Franicola D et al. Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 2008; 19: 820–826.
Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X et al. Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 2006; 12: 4702–4713.
Mayrhofer P, Blaesen M, Schleef M, Jechlinger W . Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 2008; 10: 1253–1269.
Chen ZY, Riu E, He CY, Xu H, Kay MA . Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16: 548–556.
Riu E, Chen ZY, Xu H, He CY, Kay MA . Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 2007; 15: 1348–1355.
Suzuki M, Kasai K, Saeki Y . Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 2006; 80: 3293–3300.
Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549–551.
Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39: 457–466.
Uematsu S, Akira S . Toll-Like receptors (TLRs) and their ligands. In: Stefan B and Gunther H (eds). Handbook of Experimental Pharmacology, vol 183. Springer: Berlin, 2008, pp 1–20.
Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Therapy 2008; 15: 1593–1605.
Lindahl Allen M, Antoniou M . Correlation of DNA methylation with histone modifications across the HNRPA2B1-CBX3 ubiquitously-acting chromatin open element (UCOE). Epigenetics 2007; 2: 227–236.
Linnemann AK, Platts AE, Doggett N, Gluch A, Bode J, Krawetz SA . Genomewide identification of nuclear matrix attachment regions: an analysis of methods. Biochem Soc Trans 2007; 35: 612–617.
Manzini S, Vargiolu A, Stehle IM, Bacci ML, Cerrito MG, Giovannoni R et al. Genetically modified pigs produced with a nonviral episomal vector. Proc Natl Acad SciU S A 2006; 103: 17672–17677.
Miller AM, Dean DA . Cell-specific nuclear import of plasmid DNA in smooth muscle requires tissue-specific transcription factors and DNA sequences. Gene Therapy 2008; 15: 1107–1115.
Young JL, Zimmer WE, Dean DA . Smooth muscle-specific gene delivery in the vasculature based on restriction of DNA nuclear import. Exp Biol Med (Maywood, NJ) 2008; 233: 840–848.
Kuramoto T, Nishikawa M, Thanaketpaisarn O, Okabe T, Yamashita F, Hashida M . Use of lipoplex-induced nuclear factor-kappaB activation to enhance transgene expression by lipoplex in mouse lung. J Gene Med 2006; 8: 53–62.
Breuzard G, Tertil M, Goncalves C, Cheradame H, Geguan P, Pichon C et al. Nuclear delivery of NFkappaB-assisted DNA/polymer complexes: plasmid DNA quantitation by confocal laser scanning microscopy and evidence of nuclear polyplexes by FRET imaging. Nucleic Acids Res 2008; 36: e71.
Carpentier E, Paris S, Kamen AA, Durocher Y . Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. J Biotechnol 2007; 128: 268–280.
Pringle IA, McLachlan G, Collie DD, Sumner-Jones SG, Lawton AE, Tennant P et al. Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung. J Gene Med 2007; 9: 369–380.
Nguyen AT, Dow AC, Kupiec-Weglinski J, Busuttil RW, Lipshutz GS . Evaluation of gene promoters for liver expression by hydrodynamic gene transfer. J Surg Res 2008; 148: 60–66.
Poulsen TT, Pedersen N, Juel H, Poulsen HS . A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther 2008; 15: 563–575.
Izumo T, Ohtsuru A, Tokunaga Y, Namba H, Kaneda Y, Nagata I et al. Epstein-Barr virus-based vector improves the tumor cell killing effect of pituitary tumor in HVJ-liposome-mediated transcriptional targeting suicide gene therapy. Int J Oncol 2007; 31: 379–387.
Barton GM, Kagan JC, Medzhitov R . Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7: 49–56.
Griesenbach U, Geddes DM, Alton EW . Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006; 13: 1061–1067.
Hackett PB . Integrating DNA vectors for gene therapy. Mol Ther 2007; 15: 10–12.
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68: 2961–2971.
Yant SR, Huang Y, Akache B, Kay MA . Site-directed transposon integration in human cells. Nucleic Acids Res 2007; 35: e50.
Garrison BS, Yant SR, Mikkelsen JG, Kay MA . Postintegrative gene silencing within the Sleeping Beauty transposition system. Mol Cell Biol 2007; 27: 8824–8833.
Park CW, Park J, Kren BT, Steer CJ . Sleeping Beauty transposition in the mouse genome is associated with changes in DNA methylation at the site of insertion. Genomics 2006; 88: 204–213.
Jechlinger W . Optimization and delivery of plasmid DNA for vaccination. Exp Rev Vaccines 2006; 5: 803–825.
Ma Y, Chan CY, He ML . RNA interference and antiviral therapy. World J Gastroenterol 2007; 13: 5169–5179.
Vorhies JS, Nemunaitis J . Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Exp Rev Anticancer Ther 2007; 7: 373–382.
Rossi JJ . Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 2008; 19: 313–317.
Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537–541.
Wiznerowicz M, Szulc J, Trono D . Tuning silence: conditional systems for RNA interference. Nat Methods 2006; 3: 682–688.
Giering JC, Grimm D, Storm TA, Kay MA . Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16: 1630–1636.
Scherer LJ, Frank R, Rossi JJ . Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res 2007; 35: 2620–2628.
Li L, Lin X, Khvorova A, Fesik SW, Shen Y . Defining the optimal parameters for hairpin-based knockdown constructs. RNA (New York, NY) 2007; 13: 1765–1774.
Fewell GD, Schmitt K . Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov Today 2006; 11: 975–982.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gill, D., Pringle, I. & Hyde, S. Progress and Prospects: The design and production of plasmid vectors. Gene Ther 16, 165–171 (2009). https://doi.org/10.1038/gt.2008.183
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.183
- Springer Nature Limited
Keywords
This article is cited by
-
Effects of stepwise administration of osteoprotegerin and parathyroid hormone-related peptide DNA vectors on bone formation in ovariectomized rat model
Scientific Reports (2024)
-
Nucleic acid drug vectors for diagnosis and treatment of brain diseases
Signal Transduction and Targeted Therapy (2023)
-
The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease
3 Biotech (2020)
-
Etanercept-Synthesising Mesenchymal Stem Cells Efficiently Ameliorate Collagen-Induced Arthritis
Scientific Reports (2017)
-
Cardiac gene therapy: are we there yet?
Gene Therapy (2016)